Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cancer Res. 2021 Apr 9;81(13):3693–3705. doi: 10.1158/0008-5472.CAN-20-3182

Figure 1. Tumor growth and survival of immune checkpoint blockade therapy in two murine tumor models with different sensitivity.

Figure 1.

(A and D) Growth kinetics of each tumor. MC38 or B16-F10 inoculated mice were treated with either Isotype control Ab, anti-PD-L1 Ab, or combination anti-PD-L1 Ab + anti-CTLA-4 Ab on days 9, 12, and 15 post tumor inoculation (n = 5 per group). Data are shown as mean ± SE at each time point. (B and E) Kaplan-Meier survival curve for each tumor (MC38; n = 10 per group, B16-F10; n =7-10 per group). Survival refers to the time before reaching the maximally allowed tumor volume of 2,000 mm3. (C and F) Bar plot of survival from figure B and E. Data are shown as mean ± SE. Statistical significance between groups was determined by log-rank test for B and E, and by Tukey-Kramer test for C and F. *p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001.